Does Scripps Health Cover Prolia? What Women Need to Know About Insurance, Osteoporosis, and Denosumab

Does Scripps Health Actually Cover Prolia?

Scripps Health is a San Diego-based integrated health system that offers care through employed physicians and contracts with multiple insurance carriers, including Scripps Health Plan, Blue Shield, Aetna, and Medicare Advantage products administered through various payers. Whether Prolia is covered depends on which plan you hold, not simply on whether your provider is affiliated with Scripps.

The short answer: yes, most plans affiliated with Scripps Health do cover Prolia for women who meet clinical criteria, but coverage is almost never automatic. Prior authorization is standard practice.

How Scripps Health Plan Structures Drug Coverage

Scripps Health Plan (the insurer, separate from Scripps Health the hospital system) places specialty injectables like Prolia on Tier 3 or Tier 4 of its formulary in most plan years. Tier placement directly determines your copay or coinsurance. A Tier 4 specialty drug can cost you 20-33% of the drug's list price per dose without assistance programs.

Prolia's list price is approximately $1,500 per dose as of early 2025, meaning an unassisted Tier 4 cost-share could reach $300-$500 per injection, twice yearly. That math matters before you agree to the prescription.

What Prior Authorization Typically Requires

Most Scripps-affiliated commercial plans require documentation of at least one of the following before they approve Prolia:

• A DXA-confirmed T-score of <-2.5 at the lumbar spine, total hip, or femoral neck
• A fragility fracture (hip or vertebral) regardless of T-score
• Failure of or intolerance to an oral bisphosphonate (usually alendronate or risedronate for at least 6-12 months)
• High FRAX 10-year fracture probability (major osteoporotic fracture risk >20%, or hip fracture risk >3%) as defined by the National Osteoporosis Foundation

For Medicare Advantage plans run through Scripps-affiliated networks, coverage follows Medicare Part B rules because Prolia is administered in a clinical office setting. Medicare Part B covers Prolia when billed as a physician-administered injectable for postmenopausal osteoporosis, typically at 80% after your Part B deductible.

What Is Prolia and Why Do Women Use It?

Prolia is the brand name for denosumab, a human monoclonal antibody that targets RANK Ligand (RANKL), a protein that activates osteoclasts, the cells that break down bone. By blocking RANKL, denosumab slows bone resorption and increases bone mineral density (BMD).

The FREEDOM trial, the landmark phase 3 study in postmenopausal women with osteoporosis, showed that denosumab reduced new vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 3 years compared with placebo. Those are large effect sizes for a bone drug.

Which Women Are Most Likely to Need Prolia

Osteoporosis is predominantly a women's disease. Women account for approximately 80% of the 10 million Americans with osteoporosis, and the condition is directly tied to estrogen loss at menopause. Bone loss accelerates in the 2-3 years before the final menstrual period and continues at a faster rate for the first 5-7 years after menopause.

Prolia is approved for and commonly used in:

• Postmenopausal women with osteoporosis at high fracture risk
• Women on aromatase inhibitors (anastrozole, letrozole, exemestane) for breast cancer, who experience accelerated bone loss as a direct drug effect
• Women receiving androgen deprivation therapy for certain cancers (a less common but real use case)
• Men with osteoporosis and glucocorticoid-induced osteoporosis (separate FDA indications, different dose schedule)

Life-Stage Differences in Bone Loss

Reproductive years. Young women with amenorrhea from hypothalamic dysfunction, PCOS-related anovulation, or low body weight may show bone loss years before menopause. Prolia is not typically used in this group because of its pregnancy contraindication (see below) and because restoring the hormonal cause usually restores bone.

Perimenopause. Estrogen fluctuates and then falls. DXA screening is not routinely recommended before age 65 for average-risk women, but The Menopause Society (formerly NAMS) recommends earlier DXA for women with clinical risk factors including early menopause, fragility fracture history, or prolonged glucocorticoid use. Prolia is rarely the first-line choice in perimenopausal women; bisphosphonates or hormone therapy are usually preferred first.

Postmenopause. This is the primary target population for Prolia. The FREEDOM extension data, published through 10 years of follow-up, showed continued BMD gains and sustained fracture risk reduction with long-term denosumab, which is unlike bisphosphonates that plateau.

Women with breast cancer. Aromatase inhibitors are now standard adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. They suppress residual estrogen production and cause bone loss averaging 1-3% per year at the spine. ACOG and ASCO jointly note that denosumab is an appropriate option for fracture prevention in this population.

Pregnancy and Lactation: Prolia Is Contraindicated

Prolia must not be used during pregnancy. This is not a gray-area caution. Denosumab is classified by the FDA as contraindicated in pregnancy based on animal reproduction studies showing fetal harm, including absent lymph nodes, abnormal bone development, and neonatal mortality.

The FDA prescribing information for Prolia states: "Prolia can cause fetal harm when administered to a pregnant woman based on findings from animal studies and the drug's mechanism of action."

What This Means If You Are of Reproductive Age

If you are premenopausal and your provider is considering Prolia for glucocorticoid-induced osteoporosis or another indication:

• You must use effective contraception throughout treatment and for at least 5 months after the last dose. RANKL is expressed in developing fetal bone and lymph nodes, and denosumab has a long tissue half-life.
• Pregnancy testing before each dose is recommended by many clinicians, though not explicitly mandated in the label for all indications.
• Discuss bisphosphonate alternatives with your provider if you might become pregnant. Bisphosphonates carry their own fetal bone concerns, but the data profile and clinical approach differ.

Lactation

There are no human data on denosumab transfer into breast milk. Because immunoglobulins are present in colostrum and the drug's potential for harm to a nursing infant is unknown, the FDA labeling advises against breastfeeding during treatment and for 5 months after the final dose. Women who are postpartum and need bone treatment should discuss alternatives with their clinician.

Contraception Requirements

• Use a highly effective method (IUD, implant, combined hormonal contraception, or condoms plus spermicide as a minimum) throughout Prolia treatment.
• Continue contraception for 5 months after stopping Prolia.
• Report any pregnancy immediately to your provider and to Amgen's pregnancy surveillance program.

How to Check Your Specific Scripps Coverage

Insurance coverage is plan-specific. These five steps will get you a real answer faster than any general article can.

Step 1: Pull Your Summary of Benefits and Coverage

Log into your Scripps Health Plan member portal or your insurer's website (Aetna, Blue Shield, etc.) and download your Summary of Benefits and Coverage (SBC). Search the document for "denosumab" or "Prolia." The formulary tier and cost-share percentage are listed there.

Step 2: Call Member Services Before Your Appointment

Call the number on the back of your insurance card and ask specifically:

• Is denosumab (Prolia) on my formulary?
• What tier is it on?
• What prior authorization criteria apply?
• Is there a step-therapy requirement (i.e., must I try alendronate first)?
• If it is covered under medical (Part B-type) vs. Pharmacy benefit, which applies?

Write down the representative's name, the date, and the reference number for the call. This documentation protects you if there is a dispute later.

Step 3: Ask Your Scripps Provider to Submit Prior Auth Proactively

Your Scripps rheumatologist, endocrinologist, or OB-GYN can submit a prior authorization request before your first dose. The request should include your DXA report with T-scores, FRAX score, fracture history, and any prior bisphosphonate trial notes.

Step 4: Understand the Medical vs. Pharmacy Benefit Split

Prolia is injected in a clinical office setting every 6 months, which means it is often billed under your medical benefit (like a procedure) rather than your pharmacy benefit. This matters because your deductible and out-of-pocket maximum may work differently between the two. Ask your Scripps billing team which benefit applies.

Step 5: Apply for Amgen's Copay and Patient Assistance Programs

Even with insurance, your share of the cost may be significant. Amgen offers:

• Prolia Bone Support Program for commercially insured patients: may reduce cost-share to as low as $0 per dose (income and plan-type restrictions apply).
• Amgen Safety Net Foundation: for uninsured or underinsured women who meet income criteria, Prolia may be provided at no cost.

Visit Amgen's program page or ask your Scripps provider's office to refer you to their specialty pharmacy team, who can handle enrollment.

Who Is Right for Prolia, and Who Should Consider Alternatives

This decision framework is based on current American College of Rheumatology and Endocrine Society clinical practice guidelines for postmenopausal osteoporosis, adapted specifically for women across life stages.

Women Who Are Good Candidates for Prolia

• Postmenopausal women with T-score <-2.5 who cannot tolerate oral bisphosphonates (upper GI problems, esophageal motility issues, inability to remain upright 30-60 minutes after dosing)
• Women with chronic kidney disease (CKD stage 3b-5) where bisphosphonate use is limited by creatinine clearance thresholds
• Women on aromatase inhibitors for breast cancer with documented bone loss
• Women who have already had a hip or vertebral fracture and need fast, potent fracture risk reduction
• Women who prefer a twice-yearly injection over daily or weekly oral pills

Women Who Should Consider Alternatives First

• Premenopausal women who may become pregnant (bisphosphonates, or ideally treating the hormonal root cause)
• Women in early perimenopause with osteopenia (T-score -1.0 to -2.4) and no fracture: menopausal hormone therapy or a bisphosphonate may be sufficient and has a better studied discontinuation profile
• Women with hypocalcemia: Prolia lowers calcium further and must not be started until hypocalcemia is corrected
• Women planning to stop osteoporosis treatment in the next 1-2 years: Prolia discontinuation without transition to a bisphosphonate causes rapid bone loss and a documented rebound vertebral fracture risk. A 2019 study in JAMA Internal Medicine found that women who stopped denosumab without transitioning to a bisphosphonate had vertebral fracture rates exceeding those of the original placebo group in the FREEDOM trial.

The Discontinuation Problem Is Specific to Women

Because Prolia's target population is predominantly female and because the drug is now widely prescribed, the rebound fracture risk after stopping has become a women's-health safety issue that deserves plain language. If you start Prolia, you are making a long-term commitment unless your provider transitions you to a bisphosphonate like zoledronic acid to hold the bone gains. Discuss this plan at the outset, not after several years of injections.

Prolia Versus Other Osteoporosis Options: A Quick Comparison for Women

| Treatment | Route | Fracture Data | Key Women's-Health Consideration | |---|---|---|---| | Alendronate (Fosamax) | Oral weekly | Vertebral -47%, Hip -51% (FIT trial) | GI side effects; avoid in severe CKD | | Zoledronic acid (Reclast) | IV yearly | Vertebral -70%, Hip -41% (HORIZON trial) | Convenient for women with pill adherence challenges | | Prolia (denosumab) | SC every 6 months | Vertebral -68%, Hip -40% (FREEDOM trial) | Requires transition plan on discontinuation | | Teriparatide (Forteo) | Daily SC injection | Vertebral -65% (FPT trial) | Anabolic; max 2 years; expensive | | Romosozumab (Evenity) | Monthly SC x 12 | Vertebral -73%, Hip -38% (ARCH trial) | Cardiovascular risk signal; not for women with prior MI or stroke | | Menopausal HT | Oral or transdermal | Fracture reduction confirmed in WHI | Dual benefit: vasomotor symptoms plus bone; first-line in symptomatic perimenopause |

Menopausal hormone therapy remains a valid bone-protective option for women in early menopause who also have vasomotor symptoms. The Menopause Society's 2023 position statement confirms fracture risk reduction as an evidence-based benefit of HT when started before age 60 or within 10 years of menopause onset.

Side Effects Women Ask About Most

Prolia is generally well tolerated, but several side effects are worth knowing before you start.

Hypocalcemia

Low calcium is the most clinically significant acute risk, particularly in women with vitamin D deficiency or CKD. Your provider should check calcium and 25-hydroxyvitamin D before the first dose. Amgen's prescribing label recommends supplementing with at least 1,000 mg calcium daily and 400 IU vitamin D daily throughout treatment.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is rare with the osteoporosis dose of Prolia (much more common at the higher oncology doses). Published incidence estimates for osteoporosis-dose denosumab range from less than 0.1% to 0.3% over 5 years. See your dentist before starting and avoid invasive dental procedures during active treatment if possible.

Atypical Femoral Fracture

Also rare, and more associated with long-term bisphosphonate use than denosumab, but reported with Prolia after several years of use. Hip or thigh pain during treatment warrants imaging.

Infections

RANKL is part of immune regulation. Prolia has a small but statistically significant association with serious skin infections (cellulitis) and urinary tract infections, both of which are relevant to women.

Bone Health Across the Menstrual Cycle and Hormonal Conditions

This is an area where women's physiology diverges from the male-default clinical model.

PCOS. Women with PCOS have complex bone phenotypes. Elevated androgens may be partially protective for bone, but insulin resistance and irregular cycles complicate the picture. A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found no consistent difference in fracture risk in PCOS, but monitoring is still advised in women with prolonged amenorrhea.

Premature ovarian insufficiency (POI). Women diagnosed with POI before age 40 face decades of estrogen deficiency and substantially elevated fracture risk compared with age-matched peers. ACOG Practice Bulletin No. 234 and POI-specific guidelines recommend hormone therapy at least until the average age of menopause (51 years) to protect bone. Prolia may still be needed in POI if HT is contraindicated, but this is individualized.

Postpartum bone loss. Pregnancy-associated osteoporosis is rare but real. Lactation causes transient, reversible bone loss through parathyroid hormone-related protein (PTHrP)-driven calcium transfer into breast milk. Studies show BMD recovers to baseline within 6-12 months after weaning in most women. Prolia is contraindicated during this period.

What Scripps Providers Typically Do Before Prescribing Prolia

Based on published guidelines from The Endocrine Society and typical clinical practice at integrated health systems:

1. DXA scan (baseline T-scores at spine, hip, femoral neck)
2. FRAX score calculation with or without DXA input
3. Labs: comprehensive metabolic panel, 25-hydroxyvitamin D, PTH, calcium, complete blood count
4. Dental evaluation if recent dental history is unclear
5. Review of prior treatment history (bisphosphonate trial or contraindication documentation)
6. Shared decision-making conversation including the discontinuation risk and transition plan

Your Scripps provider submits all of this to the insurer as part of the prior authorization package.

A Note on Evidence Gaps in Women

Women were the majority of subjects in the FREEDOM trial and most denosumab fracture trials, which is better than the situation for many drugs. The evidence base for Prolia in postmenopausal osteoporosis is genuinely strong. The weaker evidence areas are:

• Premenopausal use (very limited data, mostly case series)
• Women with rare bone diseases beyond osteoporosis
• Long-term data beyond 10 years from the FREEDOM extension

For younger women or those with atypical presentations, the data supporting Prolia is extrapolated from the postmenopausal population, and your provider should name that gap directly.